StockNews.com Begins Coverage on Fresenius Medical Care (NYSE:FMS)

Stock analysts at StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report issued on Thursday. The firm set a “strong-buy” rating on the stock.

Other equities analysts have also issued research reports about the stock. Truist Financial lifted their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. Berenberg Bank initiated coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target for the company.

Fresenius Medical Care Trading Down 2.0 %

Shares of FMS stock opened at $22.02 on Thursday. Fresenius Medical Care has a 1-year low of $17.93 and a 1-year high of $22.76. The firm’s 50-day simple moving average is $20.97 and its 200-day simple moving average is $20.33. The firm has a market cap of $12.92 billion, a P/E ratio of 18.20, a PEG ratio of 1.03 and a beta of 0.91. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.

Hedge Funds Weigh In On Fresenius Medical Care

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Wulff Hansen & CO. boosted its holdings in Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after acquiring an additional 325,439 shares during the period. Moran Wealth Management LLC boosted its stake in shares of Fresenius Medical Care by 47.0% in the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after purchasing an additional 74,621 shares during the period. Quantinno Capital Management LP grew its holdings in Fresenius Medical Care by 78.9% during the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after purchasing an additional 48,554 shares in the last quarter. Triasima Portfolio Management inc. increased its stake in Fresenius Medical Care by 27.4% during the 2nd quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock worth $1,631,000 after buying an additional 18,360 shares during the period. Finally, Franklin Resources Inc. lifted its holdings in Fresenius Medical Care by 3.3% in the 3rd quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock worth $1,490,000 after buying an additional 2,386 shares in the last quarter. Institutional investors and hedge funds own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.